SGNTV-002: Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Seattle Genetics, Inc
Start Date
January 11, 2019
End Date
September 12, 2023
Administered By
Duke Cancer Institute
Awarded By
Seattle Genetics, Inc
Start Date
January 11, 2019
End Date
September 12, 2023